The Uromigos Episode 156: ASCO GU 2022 First-Line Olaparib and Durvalumab in Bladder Cancer

By The Uromigos - Last Updated: February 18, 2022

Dr. Jonathan Rosenberg describes the results of a positive randomized phase 2 trial presented at the 2022 ASCO GU Symposium. He served as PI for the trial, which compared durvalumab plus placebo and durvalumab plus olaparib in a difficult-to-treat patient population.

Post Tags:Uromigos-ASCO GUUromigos-Bladder Cancer
Did you like this article?